Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View National Institutes of Health (NIH) Office of Science Policy (OSP): Request for Information on Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning To ensure consideration, comments must be submitted in writing by July 22, 2024.
View Prospective Grant of an Exclusive Patent License: T Cell Receptor Fusion Proteins for the Treatment of Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before June 4, 2024 will be considered.
View Prospective Grant of an Exclusive Patent License: Antibody-Drug Conjugates (ADCs) for Targeting CD56-Positive Tumors Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before May 28, 2024 will be considered.
View Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Polyvalent Vaccines and Methods for Making Them Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases on or before May 6, 2024 will be considered.
View Prospective Grant of an Exclusive Patent License: Adoptive T Cell Therapy Products Produced Using a Pharmacological p38 Mitogen-Activated Protein Kinase (MAPK) Inhibitor Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 8, 2024 will be considered.
View Prospective Grant of an Exclusive Patent License: Manufacturing of Anti-Malaria Monoclonal Antibody L9LS in Transgenic Cows and Sheep Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before April 4, 2024 will be considered.
View Prospective Grant of an Exclusive Patent License: Vaccine Augmented Adoptive Cell Therapy for the Treatment of Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before February 22, 2024 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Thermally Responsive T Cell Therapies for the Treatment of HPV-Positive Cancer(s) Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 24, 2024 will be considered.
View Notice and Request for Comments on the Implications of Access and Benefit Sharing (ABS) Commitments/Regimes and Other Proposed Commitments Being Considered Under a WHO Convention, Agreement or Other International Instrument on Pandemic Prevention, Preparedness and Response To be assured consideration, written comments must be received by 5 p.m. Eastern time on January 22, 2024. Written comments should be emailed to OGA.RSVP@hhs.gov with the subject line ``Written Comment Re: Implications of Access and Benefit Sharing (ABS) Commitments/Regimes and Other Proposed Commitments in the WHO Pandemic Agreement'' by January 22, 2024. Comments received after that date will be considered to the extent practicable.
View Prospective Grant of an Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer Only written comments and/or applications for a license which are received by the National Center for Advancing Translational Sciences' Office of Strategic Alliances on or before November 17, 2023 will be considered.
View Prospective Grant of Exclusive Patent Commercialization License: Human Monoclonal Antibodies That Broadly Target Coronaviruses Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases on or before November 3, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered T Cell Therapies for the Treatment of Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before October 12, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered T Cell Therapies for the Treatment of HPV-Positive Cancer(s) Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before October 6, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before August 28, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Caspase Inhibitors Only written comments and/or applications for a license which are received by the National Center for Advancing Translational Sciences' Office of Strategic Alliances on or before August 7, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: Predicting Patient Response to Cancer Therapy via Histopathology Images Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before May 22, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 21, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Metarrestin and Its Analogs for the Treatment of Metastatic Cancers Only written comments and/or applications for a license which are received by the National Center for Advancing Translational Sciences' Office of Strategic Alliances on or before April 12, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: The Development of a CD276 Antibody-Drug Conjugate (ADC) for the Treatment of Solid Tumors Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 20, 2023 will be considered.
View Prospective Grant of Exclusive Patent License: Novel Therapeutics for the Treatment of Neurodegenerative Disorders Only written comments and/or applications for a license which are received by the National Institute of Neurological Disorders and Stroke Technology Transer Office by February 24, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: Small Cell Lung Cancer Subtyping Using Plasma Cell-Free Nucleosomes Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before February 6, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Natural Killer Cell Therapies for Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 17, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 13, 2023 will be considered.
View Prospective Grant of an Exclusive Patent License: Use and Development of RAB13 and NET1 Targeting Antisense Oligonucleotides in the Treatment of Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 21, 2022 will be considered.
View Prospective Grant of Exclusive Patent License: Radiotherapeutics for Nasopharyngeal Cancer Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development November 1, 2022 will be considered.